 |
|
|
| |
Doravirine Resistance Profile in Clinical Isolates and Impact of Baseline NNRTI Resistance-Associated Mutations Observed in Treatment-Naïve Participants from Phase 2 and 3 Clinical Trials
|
| |
| |
Ernest Asante-Appiah1; Johnny Lai2; Qing Li1; DongmeiYang2; Elizabeth Anne Martin1; Peter Sklar1; Daria Hazuda1; Christos J. Petropoulos2; Charles Walworth2; Jay A. Grobler1
1Merck & Co., Inc., Kenilworth, NJ, USA. 2Monogram Biosciences, South San Francisco, CA, USA
23rd International AIDS Conference (AIDS 2020: Virtual), July 6-10, 2020.
Reported by Jules Levin
|
| |
|
|
|
|
|
